Podcast Summary: Bloomberg Talks – Novo's Martin Holst Lange Talks New Weight Loss Shot
Date: February 23, 2026
Guest: Martin Holst Lange, Chief Scientific Officer, Novo Nordisk
Host: Bloomberg

Episode Overview

This episode features an in-depth interview with Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, focusing on the company's next-generation obesity drug, Cagrisema (referred to as "cac" or "cacosama" in the discussion). The conversation centers on recent clinical trial results comparing Novo's drug to Eli Lilly’s Terzide, reactions from investors, competitive strategy, future clinical trials, and Novo Nordisk’s broader obesity pipeline. The tone is analytical but pragmatic, reflecting the competitive dynamics in the obesity drug market.

Key Discussion Points & Insights

1. Clinical Trial Results and Investor Reaction

• Challenge from Investors:
  The episode opens by noting that Novo Nordisk’s latest obesity shot, Cagrisema, underperformed compared to Eli Lilly’s Terzide in a head-to-head trial (02:05).
• Lange’s Response:
  • Martin emphasizes the complexities of the trial design and the iterative learning process in drug development.
  • Quote:

    "It has been a few years since we designed the Redefine program, the program to show the weight loss potential of cacosama...We need to have what we call a bespoke titration algorithm to really allow patients to titrate the very powerful treatment in the way that they prefer." (Martin Holst Lange, 02:39)

    • He points out that some learnings about how best to titrate the drug for maximum effect could not be implemented in the most recent study (“redefined form”).
  • Comparative Efficacy:
    • Novo’s Cagrisema: 23% weight loss in the recently discussed study (03:29).
    • Lilly’s Terzide: 25% weight loss—described as “the best data that has been seen so far in similar trials.”
    • Despite underperforming compared to Terzide, the result for Cagrisema is still “very substantial and it is among the best weight losses that we’ve seen. Also among drugs in the market.” (Martin Holst Lange, 03:33)

2. Plans for Improvement & Competitive Positioning

• Martin discusses ongoing efforts to further improve Cagrisema:
  • Redefine 11 Study:
    “We’ve implemented those learnings in a study that’s currently ongoing. That study is called Redefine 11 and... only when we see those data do we know the full weight loss potential of cacosamin.” (Martin Holst Lange, 04:31)
  • Higher Doses & Pipeline:
    • Phase 3 studies with even higher doses are starting soon.
    • The pipeline includes Senegatide (starting Phase 3) and two triagonists in earlier stage trials.
    • Martin projects confidence in Novo’s competitive portfolio for both the short and longer term.

3. Pipeline Strategy and Potential for M&A

• Obesity Drug Development Philosophy:
  Martin stresses a focus not just on maximum weight loss but also minimizing side effects and addressing comorbidities (05:14).
  • “Obesity is a very complex disease and obviously we want to have drugs that provide the biggest weight loss. But we also want to have drugs that gives as few side effects as possible... And to an extent in our current portfolio we have all of that.” (Martin Holst Lange, 05:16)
• Future Offerings:
  • The upcoming Senegatide will be offered both subcutaneously and orally, showing commitment to patient choice and innovation.

4. Scientific Approach and Differentiation from Competitors

• Why Not Follow Lilly’s GLP-1/GIP Strategy?
  • Martin is asked why Novo didn’t go with the GLP-1/GIP approach that Lilly’s Terzide embodies.
  • His answer: Novo is focused on differentiated science—superior or unique efficacy, differentiated safety/tolerability.
  • Quote:

    “We need to, to follow our philosophy when we do development... We always want to see differentiated weight loss potential or efficacy potential, but also differentiated safety and tolerability. We do believe that we will see that when we see redefine 11 in terms of weight loss with cacosamma.” (Martin Holst Lange, 06:02)

  • He details the diversity of Novo’s pipeline:
    • Cagrisema (dual molecule therapy)
    • Senegatide (GLP-1/Amlin)
    • Triagonists (“the next level” multi-targeted therapies).

Notable Quotes & Memorable Moments

| Timestamp | Speaker | Quote | |-----------|------------------------|-------| | 02:39 | Martin Holst Lange | "We already last year learned that to really see the true weight loss potential of Cagrosema, it is a very powerful combination of two molecules. We need to have what we call a bespoke titration algorithm..." | | 03:29 | Martin Holst Lange | "In the study that read out today, we saw 23% weight loss for CAC—that is actually very substantial and it is among the best weight losses that we've seen." | | 03:54 | Host (Bloomberg) | "The 25% which we saw with the comparative drug [Lilly's Terzide] is actually the best data that has been seen so far in similar trials, which is a little bit surprising..."| | 04:31 | Martin Holst Lange | "We've implemented those learnings in a study that's currently ongoing. That study is called Redefine 11... only when we see those data do we know the full weight loss potential of Cacosama." | | 05:14 | Host (Bloomberg) | "Martin, on that pipeline you seem confident on it. Would you like to see that bolstered by some M&A by bringing in organic growth to the pipeline too?"| | 05:16 | Martin Holst Lange | "Obesity is a very complex disease and obviously we want to have drugs that provide the biggest weight loss. But we also want to have drugs that gives as few side effects as possible..." | | 06:02 | Martin Holst Lange | "We need to, to follow our philosophy when we do development... We always want to see differentiated weight loss potential or efficacy potential, but also differentiated safety and tolerability." |

Timestamps for Key Segments

• 02:05: Host introduces the clinical trial outcome and investor reaction.
• 02:39: Martin Holst Lange explains trial design and importance of titration.
• 03:29: Weight loss figures for Cagrisema vs. Terzide discussed.
• 04:31: Discussion of next steps—Redefine 11 study and pipeline expansion.
• 05:14: Host presses on the pipeline and possibility of M&A.
• 06:02: Rationale behind Novo’s diverging scientific approach.

Closing

Martin Holst Lange expresses confidence in Novo Nordisk’s long-term competitive position, pointing to a robust pipeline with multiple next-generation candidates and a strong commitment to differentiated scientific approaches. While acknowledging the powerful data from Eli Lilly’s competitor, he underscores Novo’s strategic focus on both efficacy and safety, and the importance of ongoing innovation.

End of summary.